Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study

Study (n=2251) found patients who receive checkpoint inhibitors for metastatic melanoma remain at risk for development of new primary cutaneous melanomas (42 [1.9%] diagnosed with 48 melanomas, at median of 397.5 days after initiation; incidence rate ~ 1100/100 000 person-years).

JAMA Dermatology